Embed Size (px)
Vaccine 31S (2013) G81
Contents lists available at ScienceDirect
journa l homepage: www.e lsev ier .com/ locate /vacc ine
isclosure of financial support
Tel.: +34 932607812; fax: +34 932607787.E-mail address: [email protected]
This project has been coordinated by the Cancer Epidemiologyesearch Program (CERP) at the Catalan Institute of Oncology –
nstitut Català d’Oncologia (ICO) in Barcelona, Spain.We acknowledge with gratitude the support received from the
ollowing government and corporate organizations:
Partial support for this project was received from The Bill andMelinda Gates Foundation (grant reference V20-181-15) for thedevelopment of the WHO/ICO Information Centre on HPV andCancer;Spanish public grants from Instituto de Salud Carlos III (Span-ish Government) (grants RCESP C03/09, RTICESP C03/10, RTICRD06/0020/0095, RD12/0036/0056 and CIBERESP) and from theAgència de Gestió d’Ajuts Universitaris i de Recerca – Gen-eralitat de Catalunya (Catalan Government) (grants AGAUR2005SGR00695 and AGAUR 2009SGR126), and from B-DEBATEInternational Center for Scientific Debate Barcelona/BIOCAT.
The ICO Monograph Series on HPV and Disease Prevention haseceived additional support from:
GlaxoSmithKline AbbottMerck & Co.Sanofi Pasteur MSD
Becton DickinsonGenomicaHologic/Gen-Probe/GrifolsRoche Molecular Diagnostics/MTM
264-410X/$ – see front matterttp://dx.doi.org/10.1016/j.vaccine.2013.10.005
No financial sponsor, public or private, intervened in the iden-tification of topics, selection of editors or in the preparation orapproval of the Monograph series. Representatives from public andprivate financial sponsors were invited as observers to the peer-review meeting held in Sitges, Barcelona, Spain in March 21–24,2012.
The authors are solely responsible for the contents of each indi-vidual chapter. The statements and conclusions described mightnot necessarily represent the views or the position of the orga-nizations or institutions in which they serve. Each author wasrequested to disclose any potential conflict of interests and a sum-mary of the individual disclosure is presented at the end of eacharticle.
F. Xavier Boschon behalf of the Editors
Cancer Epidemiology Research Program (CERP),Catalan Institute of Oncology – Institut Català d’Oncologia (ICO),
Avda. Gran Via 199-203, 08908 L’Hospitalet de Llobregat,Barcelona, Spain